

Meiji Seika to launch two products from Santen Pharma in Indonesia

07 August 2019 | News

The two products are - Dry-eye treatment DIQUAS ophthalmic solution 3% (Diquafosol Sodium) and Glaucoma and ocular hypertension treatment TAFLOTAN ophthalmic solution 0.0015% (Tafluprost)



Meiji Seika Pharma Co., Ltd. “Meiji” has announced that it launched the following two products from Santen Pharmaceutical Co., Ltd. “Santen” in Indonesia, based on a working business agreement that Meiji entered in November of 2018 with Santen.

Dry-eye treatment

DIQUAS ophthalmic solution 3% (Diquafosol Sodium)

Glaucoma and ocular hypertension treatment

TAFLOTAN ophthalmic solution 0.0015% (Tafluprost)

Based on the working business agreement with Santen, these products will be marketed in Indonesia by Meiji’s affiliated subsidiary, PT. Meiji Indonesian Pharmaceutical Industries “PT. Meiji”. PT. Meiji established a new marketing team specialized on ophthalmic treatments, and Santen will support their marketing activities. Moving forward, PT. Meiji will continue to add more products and expand the product lineup. PT. Meiji and Santen work together to expand market share in Indonesia for ophthalmic products.

Meiji and Santen, through the marketing of ophthalmic treatments in Indonesia, are contributing to the health of the peoples of ASEAN countries.